A new MET kinase inhibitor, PLB-1001, was applied in a Phase I clinical trial that enrolled MET-altered chemo-resistant glioma patients and achieved a partial response in at least two patients with advanced secondary glioblastoma without any significant side effects [55]. The gene discussed is MET; the disease is central nervous system cancer.